Nalaganje...
Phase I trial of FOLFIRI in combination with sorafenib and bevacizumab in patients with advanced gastrointestinal malignancies
BACKGROUND: A previous phase II trial in patients with chemorefractory metastatic colorectal cancer demonstrated a 63 % disease control rate with a combination of bevacizumab and sorafenib. This phase I trial sought to determine the maximum tolerable dose (MTD) of bevacizumab and sorafenib combined...
Shranjeno v:
| izdano v: | Invest New Drugs |
|---|---|
| Main Authors: | , , , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2015
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4729450/ https://ncbi.nlm.nih.gov/pubmed/26581401 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-015-0308-5 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|